Get the Stockscreener App
3.56
5.32%
-0.20
Recursion Pharmaceuticals Inc stock is traded at $3.56, with a volume of 20.73M.
It is down -5.32% in the last 24 hours and up +17.11% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
See More
Previous Close:
$3.76
Open:
$3.8
24h Volume:
20.73M
Relative Volume:
1.15
Market Cap:
$1.89B
Revenue:
$66.41M
Net Income/Loss:
$-559.78M
P/E Ratio:
-2.9612
EPS:
-1.2022
Net Cash Flow:
$-328.09M
1W Performance:
-6.32%
1M Performance:
+17.11%
6M Performance:
-23.61%
1Y Performance:
-37.71%
1-Day Range:
$3.44
$3.80
1-Week Range:
$3.44
$4.09
52-Week Range:
$2.77
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.56 | 1.89B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool
Recursion Pharmaceuticals (RXRX) Highlights Clinical Progress, Is The Stock Fully Priced? - simplywall.st
Recursion Pharmaceuticals Stock (RXRX) Opinions on Biotech AI Prospects - Moomoo
Form 144 RECURSION PHARMACEUTICALS For: 10 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) Goldman Sachs 46th Annual Global Healthcare Conference 2025 summary - Quartr
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Insider Sell: Blake Borgeson Sells 40,000 Shares of Recursion Ph - GuruFocus
Form 4 Recursion Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals director Borgeson sells $158,500 stock By Investing.com - Investing.com India
Recursion Pharmaceuticals director Borgeson sells $158,500 stock - Investing.com
Form 144 RECURSION PHARMACEUTICALS For: 9 July By Investing.com - Investing.com Canada
Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires? - Insider Monkey
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
Form 144 RECURSION PHARMACEUTICALS For: 8 July By Investing.com - Investing.com Nigeria
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Citi's Biopharma Back to School Conference Summary - Quartr
$Recursion Pharmaceuticals (RXRX.US)$Hey everyone, is this symbol that looks like a 🎲 indicating a buy or a sell? Please help! - Moomoo
Is Recursion (RXRX) Gaining Lasting Strategic Credibility From Its Expanded Russell Index Presence? - simplywall.st
Form 144 RECURSION PHARMACEUTICALS For: 7 July By Investing.com - Investing.com Canada
RXRX: Founder’s 40,000 Class A shares listed; insider sales reported (RXRX) - Stock Titan
Recursion Pharmaceuticals (NASDAQ:RXRX) stock gains as short interest and Russell flows hit AI-biotech rally - TechStock²
Form 144 RECURSION PHARMACEUTICALS For: 6 July By Investing.com - Investing.com Canada
Insider sells 340,440 RXRX shares (NASDAQ: RXRX) - Stock Titan
Recursion Pharmaceuticals (RXRX) Is Up 8.0% After Russell Index Additions Expand Its Investor Base – Has The Bull Case Changed? - Yahoo Finance
Recursion Pharmaceuticals (RXRX) Stock Looks Fully Valued Despite AI Drug Hopes - Yahoo Finance
Recursion Pharmaceuticals (NASDAQ:RXRX) beats out biotech funds as filings, spending become focus - TechStock²
Recursion Pharmaceuticals Stock (RXRX) Opinions on Technical Consolidation - Quiver Quantitative
Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock - Investing.com
Recursion Pharmaceuticals director Blake Borgeson sells $105,600 in stock By Investing.com - Investing.com UK
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026? - The Motley Fool
RXRX rallies past biotech ETFs as short interest, insider-sale filings shape coming week - TechStock²
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Dar Zavain - Moomoo
RXRXRecursion Pharmaceuticals Inc Volatility & Greeks - Finviz
Recursion Pharmaceuticals (NASDAQ:RXRX) pops, short interest still much bigger than new founder-sale alert - TechStock²
Form 4 Recursion Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
Recursion Pharmaceuticals (RXRX) director granted 5,109 Class A shares - Stock Titan
Recursion (NASDAQ: RXRX) director Dean Y. Li receives 3,747-share equity grant - Stock Titan
RXRX Stock Draws ARK Buying As AI Drug Story Builds - timothysykes.com
Christopher C. Gibson lists multiple Class A sales (RXRX) - Stock Titan
Form 144 RECURSION PHARMACEUTICALS For: 1 July By Investing.com - Investing.com Canada
RXRX (NASDAQ: RXRX) insider sale notice — 100,000 Class A shares - Stock Titan
Anthropic Launches Claude Science to Enter Life Sciences, AI Drug Discovery Stocks Tumble in Response - NAI500
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Does Recursion (RXRX) Russell Value Index Lift Recast Its AI Biotech Story as Deep Value? - simplywall.st
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Recursion Pharmaceuticals Inc Stock (RXRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Jul 07 '26 |
Sale |
3.96 |
40,000 |
158,500 |
6,218,287 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):